RT Journal Article
T1 Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis
A1 Abbadessa, Anna
A1 Núñez Bernal, Paulina
A1 Buttitta, Giorgio
A1 Ronca, Alfredo
A1 D'Amora, Ugo
A1 Zihlmann, Carla
A1 Stiefel, Niklaus
A1 Ambrosio, Luigi
A1 Malda, Jos
A1 Levato, Riccardo
A1 Crecente Campo, José
A1 Alonso Fernández, María José
AB Pathological angiogenesis is a crucial attribute of several chronic diseases such as cancer, age-related macular degeneration, and osteoarthritis (OA). In the case of OA, pathological angiogenesis mediated by the vascular endothelial growth factor (VEGF), among other factors, contributes to cartilage degeneration and to implants rejection. In line with this, the use of the anti-VEGF bevacizumab (BVZ) has been shown to prevent OA progression and support cartilage regeneration. The aim of this work was to functionalize a medical grade collagen with poly (lactic-co-glycolic acid) (PLGA) microparticles containing BVZ via three-dimensional (3D) printing to target pathological angiogenesis. First, the effect of several formulation parameters on the encapsulation and release of BVZ from PLGA microparticles was studied. Then, the anti-angiogenic activity of released BVZ was tested in a 3D cell model. The 3D printability of the microparticle-loaded collagen ink was tested by evaluating the shape fidelity of 3D printed structures. Results showed that the release and the encapsulation efficiency of BVZ could be tuned as a function of several formulation parameters. In addition, the released BVZ was observed to reduce vascularization by human umbilical vein endothelial cells. Finally, the collagen ink with embedded BVZ microparticles was successfully printed, leading to shape-stable meniscus-, nose- and auricle-like structures. Taken altogether, we defined the conditions for the successful combination of BVZ-loaded microparticles with the 3D printing of a medical grade collagen to target pathological angiogenesis
PB Elsevier
YR 2023
FD 2023
LK http://hdl.handle.net/10347/30956
UL http://hdl.handle.net/10347/30956
LA eng
NO Journal of Controlled Release  360 (2023) 747-758
NO This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 814444 (MEFISTO). The authors thank mAbxience-GH Genhelix for the kind donation of Bevacizumab (Avastin®) and Geistlich Pharma AG for providing the medical grade collagen. AA acknowledges funding from “la Caixa” Foundation (ID 100010434) with a fellowship code LCF/BQ/PR22/11920003. RL acknowledges funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 949806, VOLUME-BIO). RL and JM acknowledge funding from the Dutch Artritis Foundation (LLP-12 and LLP-22)
DS Minerva
RD 27 abr 2026